Joint Formulary & PAD

GP

Inflammatory bowel disease

Committee Recommendations (1)

The Surrey Heartlands Area Prescribing Committee (APC) agreed an updated Inflammaory Bowel Disease (IBD) pathway for use.

Guideline Profile

Indication :
Inflammatory bowel disease
Keywords :
IBD, CD, Chronic Bowel Disorder, inflammatory bowel disease, corticosteroid, 5-ASA, aminosalicylate, UC, ulcerative Colitis, prednisolone, mesalazine, crohns, lower GI symptoms, Crohn's, Crohn's disease, biologic, NICE, biosimilar, Sequential use of biologic medicines, TNF alpha inhibitor, Cytokine modulator, NICE, immunosuppressant, interleukin (IL)23 protein, DMARD, bDMARD, tsDMARD, Disease modulating, high cost immunomodulator, JAK inhibitor, Janus Kinase, Jakinib, Interleukin, IL 12/23, Immune checkpoint inhibitors, monoclonal antibodies, leukocyte integrin, sphingosine 1-phosphate (S1P) receptor modulator, anti-interleukin-23, anti-IL-23,
Brand Names Include :
Humira, Hyrimoz, Amgevita, Hulio, Imraldi, Mylan, Yuflyma, Idacio, Jyseleca, Simponi, Remicade, Inflectra, Remsima, Flixabi, Zessly, Omvoh, Zeposia, Xeljanz, Rinvoq, Stelara, Entyvio, Entyvio SC, Skyriza,
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Supporting Documents :
4